Savara Inc Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Savara Inc (SVRA) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$35.00 thousand for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-26.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2014-03-26
- Savara Inc fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2013-12-31 was $0.00, a 100.00% decline year-over-year.
- Savara Inc fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2013-09-30 was $0.00.
- Savara Inc fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2013-06-30 was -$7.50K.
- Savara Inc fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2013-03-31 was -$27.50K.
- Savara Inc fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2013 was -$35.00K.
- Savara Inc fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2012 was -$2.38K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-26 | $0.00 derived: sum of 2 quarters · filed 2014-03-26 | -$7.50K derived: sum of 3 quarters · filed 2014-03-26 | -$35.00K 10-K · filed 2014-03-26 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-04 | -$7.50K derived: sum of 2 quarters · filed 2013-11-04 | -$35.00K 10-Q · filed 2013-11-04 | -$1.10K derived: sum of 4 quarters · filed 2013-11-04 |
| 2013-06-30 | -$7.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-05 | -$35.00K 10-Q · filed 2013-08-05 | -$1.10K derived: sum of 3 quarters · filed 2013-08-05 | -$56.38K derived: sum of 4 quarters · filed 2013-08-05 |
| 2013-03-31 | -$27.50K 10-Q · filed 2013-05-15 | $6.40K derived: sum of 2 quarters · filed 2013-05-15 | -$48.88K derived: sum of 3 quarters · filed 2013-05-15 | |
| 2012-12-31 | $33.90K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-19 | -$21.38K derived: sum of 2 quarters · filed 2013-03-19 | -$2.38K 10-K · filed 2013-03-19 | |
| 2012-09-30 | -$55.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | -$36.27K 10-Q · filed 2012-11-05 | ||
| 2012-06-30 | $19.00K 10-Q · filed 2012-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |